RxDoctor Payments Data

Alvin Bannerjee

Foot & Ankle Surgery · Washington, DCNPI 1225329873

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $985 of the $1,569 with a category attached, or 62.8%. 19 manufacturers reported payments, led by Supreme Orthopedic Systems, LLC at 39.9% of the total. Reporting peaked in 2020 at $830 and has fallen 58.3% since, to $346 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in DC, where the typical reported total is $3,977.

$1,569in general payments, 2019–2025

Across 33 payments — averaging $47.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supreme Orthopedic Systems, LLC$626
  • Treace Medical Concepts, Inc.$202
  • Bioventus LLC$151
  • Stryker$125
  • Biopro, Inc.$105
  • Amgen$58
  • plus $301 from 13 others

What the payments were for

  • Food & beverage$98563%
  • Education$58437%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,569 in reported general payments places this provider in the 30th percentile of 23 foot & ankle surgery providers in District of Columbia.

See all foot & ankle surgery providers in District of Columbia

Medicare billing

Part B allowed, 2024
$101,518
Medicare patients
327
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole34$25,214
Ciclopirox72$2,791
Gabapentin39$410
Ketoconazole11$174
Meloxicam30$140
Cephalexin13$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$42$25,21434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 23 foot & ankle surgery providers in District of Columbia.

Other foot & ankle surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →